Approval · Notice of Compliance 36625 · 2025
CREDELIO PLUS: Notice of Compliance 36625
Issued December 24, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36625
- Date
- December 24, 2025
- Company
- Elanco Canada LimitedGuelph, Ontario, Canada
- Product type
- Veterinary
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additional claim for treatment of demodicosis in dogs
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CREDELIO PLUS | 02525674 | Marketed |
| CREDELIO PLUS | 02525682 | Marketed |
| CREDELIO PLUS | 02525690 | Marketed |
| CREDELIO PLUS | 02525704 | Marketed |
| CREDELIO PLUS | 02525712 | Marketed |
Medicinal ingredients
- MILBEMYCIN OXIME 2.11 MG per TAB
- LOTILANER 56.25 MG per TAB
- MILBEMYCIN OXIME 4.22 MG per TAB
- LOTILANER 112.5 MG per TAB
- MILBEMYCIN OXIME 8.44 MG per TAB
- LOTILANER 225 MG per TAB
- MILBEMYCIN OXIME 16.88 MG per TAB
- LOTILANER 450 MG per TAB
- MILBEMYCIN OXIME 33.75 MG per TAB
- LOTILANER 900 MG per TAB